NCT00881231已完成1 期
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Eon and Otsuka (Pletal) 50 mg Cilostazol Tablets In Healthy Adults Volunteers Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 26
- 主要终点
- Bioequivalence based on AUC and Cmax
研究概览
简要总结
To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
1
Experimental
Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
干预措施: Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA) (Drug)
2
Active Comparator
Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
干预措施: Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA) (Drug)
结局指标
主要结局
Bioequivalence based on AUC and Cmax
时间窗: 21 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting ConditionsHealthyNCT00881179Sandoz24
已完成
1 期
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting ConditionsHealthyNCT00881426Sandoz26
已完成
1 期
Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mgHealthyNCT00648388Mylan Pharmaceuticals Inc44
已完成
不适用
Bioequivalency Study of Anastrozole 1 mg Under Fasted ConditionsBreast CancerNCT01155102Roxane Laboratories31
已完成
1 期
Fasted Bioavailability Study of Cilostazol Tablets, 50mgTherapeutic Equivalency, HealthyNCT00685802Mutual Pharmaceutical Company, Inc.32